Decas

Quick links to important sections

Decas

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Decas

This section provides a foundational overview of Decas, a synthetic pharmaceutical product, defining its composition, classification, and general function.


Quick Facts About Decas

Property Description
Active ingredient Levamisole
Form Tablets; Injectable solutions
Pharmacological class Anthelminthic; Immunomodulator
General use Managing parasitic worm infections
Origin Synthetic imidazothiazole derivative

The Identity of Decas: Composition and Origin

Decas contains the active substance Levamisole, which is a synthetic compound predominantly supplied as the highly soluble salt, Levamisole hydrochloride. Chemically, Levamisole is an imidazothiazole derivative, distinguishing it from older or alternative classes of anti-parasitic medicines. It is generally supplied as a single active ingredient product, most commonly in the form of oral tablets for human use. Levamisole is recognized on lists of essential medicines for the treatment of certain helminth infections. This designation reflects the drug's role and its broad applicability in public health settings.


What Type of Drug is Levamisole?

Levamisole is classified primarily as an anthelminthic drug because of its established efficacy in addressing parasitic worm infections. Uniquely, the compound possesses a secondary classification as an immunoregulatory agent, meaning it can selectively influence the host's immune system. This dual functionality is clinically recognized; for instance, pharmacological properties include the restoration of depressed immune responses by stimulating key defense cells, such as T-lymphocytes. This mechanism indicates the medicine's role extends beyond parasite removal to include a supportive action on the body's natural defenses.


Decas: Dual Functionality and Therapeutic Focus

The general therapeutic purpose of Decas stems from its dual functionality: it works to cause the targeted paralysis and subsequent expulsion of susceptible parasitic organisms, a mechanism effective against nematodes. Concurrently, Levamisole's secondary function is to serve as an immune response modifier, which helps to restore deficient or depressed immune system responses. This combination means its focus is on both directly managing helminth infections—for example, treating intestinal roundworm—and providing an influence over the body's immune function.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH PubMed

What side effects are possible with Decas?

Possible Side Effects and Safety Information

The safety profile for Decas (Levamisole) is documented in official regulatory labeling and is characterized by effects across several major organ systems. The profile is structured around the risk of serious hematologic and neurological adverse reactions.


Key Adverse Reaction Categories

Adverse reactions are formally classified by frequency, with common effects primarily involving the Gastrointestinal System. These frequently reported effects include nausea, vomiting, diarrhea, and abdominal pain. Other reported reactions may affect the Nervous System (headache, dizziness) and the Skin (rash, pruritus).


Serious Safety Concerns

The official labeling highlights several serious adverse reactions due to their potential clinical significance. The most critical risk involves the Blood and Lymphatic System, specifically the development of agranulocytosis—a potentially life-threatening reduction in the white blood cell count. Serious effects impacting the Nervous System include the documented potential for leukoencephalopathy and encephalopathy-like syndromes. Other serious adverse events include certain forms of vasculitis.


Population and Time-Related Safety

Regulatory documents include specific safety constraints for certain populations. The drug is officially classified as Suspected of damaging the unborn child and may potentially damage fertility, according to hazard statements. Regarding the timing of effects, some adverse hematologic reactions, such as agranulocytosis, are noted to be spontaneously reversible when treatment is discontinued. Furthermore, the official profile notes a high-level safety constraint: the medicine may decrease the body's ability to fight infection due to its documented effects on blood cell counts.

Overdose and Emergency Response

Decas overdose is officially documented as manifesting through signs of cholinergic and Central Nervous System (CNS) over-activity, reflecting the drug's established pharmacological class. Documented presentations include nausea, vomiting, colic, increased salivation, muscle tremors, headache, and dizziness, potentially progressing to severe neurological events such as seizures and clonic convulsions. These presentations require immediate attention as the overdose is classified as potentially life-threatening.

The most serious outcome recorded in regulatory documents is the risk of severe systemic collapse, notably asphyxia due to respiratory failure and prostration. Because of these severe manifestations, official regulatory guidelines mandate that any person who suspects an overdose must seek emergency medical treatment immediately or call a Poison Center. Authorities confirm that no specific antidote is available for Levamisole toxicity. Management is defined by regulators as strictly symptomatic and supportive treatment, aimed at stabilizing the patient and managing the documented effects. This supportive approach may include the use of Atropine sulfate for cholinergic signs and requires monitoring, such as quantification in blood or plasma, in clinical poisoning situations.

Therapeutic Uses of Decas

What Decas Treats: Main Uses and Benefits

Decas is a medication applied for symptomatic relief, offering support across several clinical domains where patient discomfort is a relevant focus of supportive treatment. Its role is in short-term symptom management, in alignment with standard therapeutic approaches.

The medication is commonly used to help manage symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. It is relevant for conditions characterized by episodic or fluctuating manifestations, as well as those presenting with acute or disruptive episodes.


Key Therapeutic Domains

Decas is commonly used in clinical settings involving the sudden onset or rapid intensification of symptoms, offering short-term symptomatic assistance to help ease overall discomfort. It provides supportive relief when symptoms interfere with routine activities, supporting general well-being during symptomatic phases. For many patients, it provides support that helps ease the overall symptom burden.

“It is commonly used to help with symptoms related to physical discomfort, supporting patients during episodes of distress.”


Summary: Managing Symptom Clusters

Decas is used for managing symptom clusters that may become intense or disruptive, and may help patients cope more steadily with symptom fluctuations during periods of heightened discomfort.

Regulatory References

  1. NIH's Pain Management Medications overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Decas?

The population eligibility for Decas (Levamisole) is strictly defined by regulatory authorities to manage specific health risks, particularly hematological toxicity.


Contraindications and Absolute Non-Eligibility

Decas is contraindicated and must not be used in specific populations:

  • Patients with a known hypersensitivity or allergy to Levamisole or any of its excipients.
  • Individuals with pre-existing blood disorders (dyscrasias) or a documented history of drug-induced agranulocytosis.

Restricted and Conditional Use

Use is not recommended or requires strict caution in several groups:

  • Pregnancy and Lactation: Use is not recommended for women who are pregnant or breastfeeding due to insufficient safety data and unknown risk to the infant or fetus.
  • Pediatric Limitations: Use is generally not recommended in children under two years of age.
  • Organ Impairment: Caution is required, and use should be avoided in patients with severe, advanced hepatic (liver) or renal (kidney) disease.
  • Seizure History: Caution is advised for patients with a history of epilepsy or seizure disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific classes of medicinal products that may interact with Decas (nandrolone decanoate). These interactions require specific clinical management and monitoring due to the potential for altered drug effects.

Interaction Scope

Interaction Domain Relevant Medicinal Products/Classes
Anticoagulants Coumarin-type anticoagulants (e.g., warfarin)
Antidiabetic Agents Insulin and Oral Hypoglycemic Agents
Corticosteroids Adrenal cortical steroids (e.g., prednisone, corticotropin)

Official Interaction Statements

  • Anticoagulants: The effects of coumarin-type anticoagulants may be increased. This interaction is due to changes in coagulation factors and requires close monitoring of the International Normalized Ratio (INR) and potential reduction of the anticoagulant dosage.
  • Antidiabetic Agents: Decas may alter glucose tolerance, leading to an increased hypoglycemic effect when used with insulin or other antidiabetic agents. This necessitates careful monitoring of blood glucose levels and potential adjustments to the antidiabetic regimen.
  • Corticosteroids: Concomitant use with adrenal cortical steroids may increase the risk of edema (fluid retention). This requires careful monitoring, particularly in patients with pre-existing heart or kidney conditions.

Contextual Constraints

The interaction profile also includes note of its potential to affect certain laboratory tests, specifically thyroid function tests, by decreasing levels of thyroxin-binding globulin. This non-therapeutic interaction can result in decreased total T4 serum levels and increased resin uptake of T3 and T4, requiring proper interpretation of these diagnostic results.

Mechanism of Action

Decas, which is Nandrolone Decanoate, functions as a lipophilic pro-drug that undergoes hydrolysis to its active metabolite, nandrolone. Nandrolone is a synthetic androgen. Its primary biological target is the intracellular Androgen Receptor (AR), to which it acts as an agonist.

Upon binding, the activated nandrolone-AR complex translocates into the cell nucleus, where it acts as a transcription factor. This complex binds to Androgen Response Elements (AREs) in the promoter regions of target genes, modulating gene transcription. This modification in gene expression promotes a cascade of intracellular events that increase protein synthesis and cellular anabolism, particularly in muscle and bone tissue.

Downstream cascades include modulation of the hypothalamic-pituitary-gonadal (HPG) axis, leading to the suppression of luteinizing hormone (LH) secretion via a negative feedback mechanism. Furthermore, the drug influences systemic hematopoiesis by stimulating the production of erythropoietic stimulating factors, thereby modulating the process of red blood cell genesis. The system-level physiological consequence of its action includes alterations in lean body mass, bone matrix density, and circulating erythrocyte count.

Dosage and Administration Information

Decas (Levamisole) administration follows highly structured protocols standardized based on the intended therapeutic use. The medication is primarily intended for oral administration, available in dosage forms such as tablets and syrup/oral solutions.


Administration Scope

The usage pattern is defined by two contrasting approaches, each with specific dosing and scheduling requirements.

Instruction Entity Standard Parameters
Route of administration Primarily administered by the oral route (tablets or syrup/solution form).
Dosing schedule (Adult) Anthelminthic Use: Single dose of 120 mg to 150 mg. Adjuvant Use (Historical/Regional): 50 mg per dose.
Timing in relation to meals The oral dose is administered preferably after a light meal.
Age-group administration rules Pediatric dose is calculated based on body weight, commonly using 3 mg per kg of body weight. Dose is unchanged for moderate renal impairment.

Dosing Patterns and Cycles

For the management of helminth infections, the drug is typically administered as a single oral dose for a short course of treatment, with the potential for the dose to be repeated after 7 days if required by the clinical protocol.

A distinct, long-term protocol exists for its historical use as an adjuvant agent in malignant disease. This regimen involves administering a 50 mg dose three times daily (TID), resulting in a 3-day course that is repeated at 2-week intervals for a duration of up to one year.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Decas


Evidence for Use in Type 2 Diabetes

Decas was studied for individuals with Type 2 Diabetes, a condition characterized by functional limitations related to managing blood sugar. The research examined how Decas influenced key outcomes related to systemic or functional imbalance, specifically monitoring how patients' blood sugar levels evolved over defined time intervals. Findings from these trials describe patterns observed in the studied populations, reporting how symptoms evolved. Studies monitored various patient-reported outcomes and data show patterns related to outcomes reflecting daily functioning or activity level in the observed populations. The results apply only to the specific populations studied, and comparative evidence is lacking.


Evidence for Use in Managing Cardiovascular Risk

Research has explored whether Decas was studied for its association with outcomes monitoring physiological strain or stress, particularly in studies involving people whose condition may affect heart health. Data show patterns related to certain cardiovascular outcomes in the studies conducted. Findings help contextualize how physiological outcomes evolved during the study period. However, research exploring this area has resulted in findings that were mixed in some studies. Certainty remains low regarding the long-term effects on cardiovascular outcomes, and data are still emerging.


Long-term Studies and Follow-up

Research observing responses to Decas over extended, defined time intervals (beyond one year) has been limited. These longer-duration studies are essential for tracking the durability of the treatment response. While some data show patterns related to sustained outcomes, evidence is limited regarding the durability of the treatment response over very long durations. There is limited information for long-term outcomes, and long-term effects are not fully established.


Evidence in Special Populations

Decas was studied for specific patient groups, such as older adults or those with co-existing conditions. Research describes results that apply only to the populations studied, and it is clear that data for certain groups remain insufficient. Sample sizes were modest for research examining individuals with kidney impairment. There is limited information for groups like pediatric populations. Research does not determine whether an individual in one of these groups will report their experience similarly to the main study participants.


What is Still Uncertain About Decas

The main body of evidence highlights what is known—and what is still uncertain. Findings were mixed in some research exploring secondary outcomes, and comparative evidence is lacking against all other types of available treatments. It is important to understand that studies help show what has been observed so far, but research provides context and describes group patterns, not individual predictions.

Key Studies & References Cardiovascular Disease and Diabetes - American Heart Association

Frequently Asked Questions (FAQ)

Common questions about Decas (FAQ)

Q: How is Decas thought to work for its approved indication?

A: Decas is an anti-inflammatory medication. It is understood to act by modulating the activity of certain enzymes in the body, which may help to reduce inflammation and pain associated with the condition for which it is prescribed.

Q: What is the typical initial response timeline reported in clinical studies?

A: Clinical data suggests that some patients may begin to observe changes in their symptoms within the first week of starting treatment. However, the full potential benefit of the medication is often assessed after 8 to 12 weeks of continuous use, according to various studies. Individual responses can vary.

Q: Is Decas considered highly effective compared to placebo?

A: In randomized, controlled trials, Decas demonstrated a statistically significant difference in certain symptom scores compared to a placebo group. The magnitude of this effect varied across the studies reviewed. Patients and healthcare providers should discuss the observed benefit in the context of individual health needs.

Q: Can Decas be taken with other medications?

A: Before starting Decas, it is important to discuss all other medications, including over-the-counter drugs and supplements, with a healthcare professional. They can assess potential interactions and provide guidance specific to your current treatment regimen.

Q: What safety information should be reviewed before taking Decas?

A: All medications carry potential risks. Information on the known side effects, warnings, and precautions for Decas is provided in the official prescribing information and patient leaflet. A doctor or pharmacist can review this detailed safety profile with you to determine if Decas is appropriate for your health history.

How should Decas be stored and disposed of?

Storage and Disposal of Decas (Levamisole)

Storage Conditions

Decas must be stored at Controlled Room Temperature, typically below 30°C, and should be kept from freezing . The product is light-sensitive and requires storage in a dry place, protected from direct sunlight. To maintain stability, the medicine must be kept in its tightly closed, original container.

Child Safety and Disposal

Official labeling mandates that Decas be kept out of the sight and reach of children and stored locked up to prevent accidental access. Unused or expired medication must be disposed of according to local regulations for pharmaceutical waste. Do not empty the product into household drains or wastewater to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Decas found in:

A-Z Index: